BOUNDLESS BIO, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
BOUNDLESS BIO, INC. (BOLD) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $12.30 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-03-09
- BOUNDLESS BIO, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-06-30 was $12.30M.
- BOUNDLESS BIO, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $12.30M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|
| 2024-12-31 | $12.30M 10-K · filed 2026-03-09 | |
| 2024-06-30 | $12.30M 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |